このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

NuCana 将来の成長

Future 基準チェック /26

NuCanaは、44.9%と75.6%でそれぞれ年率44.9%で利益と収益が成長すると予測される一方、EPSはgrowで42.9%年率。

主要情報

44.9%

収益成長率

42.9%

EPS成長率

Biotechs 収益成長	24.5%
収益成長率	75.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	17 May 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

NasdaqCM:NCNA - アナリストの将来予測と過去の財務データ ( )GBP Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2	-28	N/A	N/A	4
12/31/2025	1	-25	N/A	N/A	4
12/31/2024	N/A	-26	N/A	N/A	4
3/31/2024	N/A	-27	-22	-22	N/A
12/31/2023	N/A	-28	-27	-26	N/A
9/30/2023	N/A	-35	-34	-33	N/A
6/30/2023	N/A	-33	-22	-22	N/A
3/31/2023	N/A	-31	-25	-25	N/A
12/31/2022	N/A	-32	-24	-23	N/A
9/30/2022	N/A	-30	-27	-26	N/A
6/30/2022	N/A	-34	-30	-29	N/A
3/31/2022	N/A	-39	-25	-24	N/A
12/31/2021	N/A	-41	-25	-24	N/A
9/30/2021	N/A	-39	-23	-23	N/A
6/30/2021	N/A	-40	-28	-27	N/A
3/31/2021	N/A	-36	-25	-23	N/A
12/31/2020	N/A	-31	-23	-22	N/A
9/30/2020	N/A	-26	-18	-17	N/A
6/30/2020	N/A	-22	-21	-20	N/A
3/31/2020	N/A	-20	-25	-24	N/A
12/31/2019	N/A	-21	-25	-24	N/A
9/30/2019	N/A	-17	-24	-22	N/A
6/30/2019	N/A	-16	-19	-18	N/A
3/31/2019	N/A	-13	-17	-16	N/A
12/31/2018	N/A	-14	-14	-12	N/A
9/30/2018	N/A	-15	-14	-13	N/A
6/30/2018	N/A	-26	-12	-11	N/A
3/31/2018	N/A	-28	-11	-10	N/A
12/31/2017	N/A	-23	N/A	-9	N/A
9/30/2017	N/A	-20	N/A	-8	N/A
6/30/2017	N/A	-7	N/A	-8	N/A
3/31/2017	N/A	-6	N/A	-9	N/A
12/31/2016	N/A	-6	N/A	-9	N/A
12/31/2015	N/A	-5	N/A	-4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NCNA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: NCNA今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: NCNA今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: NCNAの収益 ( 75.6% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: NCNAの収益 ( 75.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NCNAの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

NuCana 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 9.5% to US$4.79

Price target increased by 10% to US$4.38

Price target decreased to US$3.42

Price target decreased to US$4.26

Price target decreased to US$4.26

Price target decreased to US$4.69

Recent updates

New minor risk - Shareholder dilution

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Price target increased by 9.5% to US$4.79

Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely

Insufficient new directors

New major risk - Financial position

New major risk - Revenue and earnings growth

New major risk - Share price stability

Nucana plc Announces Presentation on Ongoing Nutide:701 Study of Nuc-7738 At the Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics 2023

We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate

NuCana plc Presents Encouraging Data on NUC-3373 in Colorectal Cancer At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana plc, Annual General Meeting, Jun 15, 2023

NuCana Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Price target increased by 10% to US$4.38

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Price target decreased to US$3.42

Price target decreased to US$4.26

NuCana plc Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Price target decreased to US$4.26

NuCana: An Intriguing 'Sum Of The Parts' Story

Nucana Presents Promising Data on NUC-7738 At the European Society of Medical Oncology (Esmo) Annual Meeting 2022

NuCana GAAP EPS of -£0.07

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana regains Nasdaq compliance

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

Price target decreased to US$4.69

NuCana Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Less than half of directors are independent

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Price target decreased to US$9.00

Price target decreased to US$11.67

NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

NuCana plc Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study

We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth

NuCana: Preparing For A Critical 2022

Price target increased to US$17.25

We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow

NuCana: The Market Continues To Overlook Its ProTide Platform Technology

We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth

Forecast to breakeven in 2025

New 90-day low: US$4.38

Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth

NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

New 90-day high: US$6.40

New 90-day low: US$4.40

NuCana plc Appoints Andrew Kay as Chairman of its Board of Directors

How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?

Price target lowered to US$17.29

NuCana (NCNA) Investor Presentation - Slideshow

Nucana plc Announces Final Data from the Phase Ib Study of Acelarin Plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in the Oncologist

Price target raised to US$19.00

NuCana reports Q3 results

New 90-day low: US$4.45

NuCana plc Announces the Appointment of Bali Muralidhar, M.D., Ph.D. to Its Board of Directors

NuCana plc Announces Data from Ongoing NUC-3373, NUC-7738 and Acelarin Phase III Study

New 90-day low: US$4.58

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘